KR20040099293A - 재조합 포자 - Google Patents
재조합 포자 Download PDFInfo
- Publication number
- KR20040099293A KR20040099293A KR10-2004-7013611A KR20047013611A KR20040099293A KR 20040099293 A KR20040099293 A KR 20040099293A KR 20047013611 A KR20047013611 A KR 20047013611A KR 20040099293 A KR20040099293 A KR 20040099293A
- Authority
- KR
- South Korea
- Prior art keywords
- spores
- genetically modified
- genetic code
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 230000012010 growth Effects 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 60
- 230000002068 genetic effect Effects 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 229960005486 vaccine Drugs 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 230000035784 germination Effects 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000001086 cytosolic effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000037911 visceral disease Diseases 0.000 claims description 5
- 241001112696 Clostridia Species 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 102000009025 Endorphins Human genes 0.000 claims description 2
- 108010049140 Endorphins Proteins 0.000 claims description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 2
- 101710182223 Toxin B Proteins 0.000 claims description 2
- 238000012239 gene modification Methods 0.000 claims description 2
- 230000005017 genetic modification Effects 0.000 claims description 2
- 235000013617 genetically modified food Nutrition 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 210000001630 jejunum Anatomy 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 229940118376 tetanus toxin Drugs 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims 2
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 122
- 235000014469 Bacillus subtilis Nutrition 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 28
- 102000005936 beta-Galactosidase Human genes 0.000 description 17
- 108010005774 beta-Galactosidase Proteins 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 230000004763 spore germination Effects 0.000 description 15
- 101100162670 Bacillus subtilis (strain 168) amyE gene Proteins 0.000 description 14
- 210000003608 fece Anatomy 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 101150000850 thrC gene Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 101150077915 oppA gene Proteins 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 239000003833 bile salt Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000949031 Citrobacter rodentium Species 0.000 description 7
- 229940093761 bile salts Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 244000063299 Bacillus subtilis Species 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000607626 Vibrio cholerae Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 3
- 101150105363 amyE gene Proteins 0.000 description 3
- 101150055766 cat gene Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 229940031416 bivalent vaccine Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101100206300 Escherichia coli tetC gene Proteins 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010021432 Immunisation reaction Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710132699 Lysozyme 2 Proteins 0.000 description 1
- 102100026848 Lysozyme-like protein 2 Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000001649 Pica Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150046654 cotA gene Proteins 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940127241 oral polio vaccine Drugs 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 101150117635 tetC gene Proteins 0.000 description 1
- 108010044241 tetanus toxin fragment C Proteins 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N3/00—Spore forming or isolating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0205376.7A GB0205376D0 (en) | 2002-03-07 | 2002-03-07 | Spore germination |
| GB0205376.7 | 2002-03-07 | ||
| PCT/GB2003/000966 WO2003074681A1 (en) | 2002-03-07 | 2003-03-07 | Recombinant spores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040099293A true KR20040099293A (ko) | 2004-11-26 |
Family
ID=9932499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7013611A Withdrawn KR20040099293A (ko) | 2002-03-07 | 2003-03-07 | 재조합 포자 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050287168A1 (https=) |
| EP (1) | EP1495110A1 (https=) |
| JP (1) | JP2005519123A (https=) |
| KR (1) | KR20040099293A (https=) |
| CN (1) | CN1639322A (https=) |
| AU (1) | AU2003214391A1 (https=) |
| GB (1) | GB0205376D0 (https=) |
| RU (1) | RU2004129739A (https=) |
| WO (1) | WO2003074681A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503509D0 (en) * | 2005-02-19 | 2005-03-30 | New Royal Holloway & Bedford | An improved delivery agent |
| JP2008231063A (ja) * | 2007-03-22 | 2008-10-02 | Takano Foods Kk | 納豆菌ワクチン |
| US9610333B2 (en) * | 2008-07-11 | 2017-04-04 | Tufts University | Methods, compositions and kits for vegetative cell-based vaccines and spore-based vaccines |
| WO2010006326A2 (en) * | 2008-07-11 | 2010-01-14 | Tufts University | Methods and compositions for spore-based vaccines |
| WO2011111783A1 (ja) * | 2010-03-12 | 2011-09-15 | カルピス株式会社 | 大腸におけるビフィズス菌の増加及び減少抑制剤 |
| EP4077359B1 (en) | 2019-12-18 | 2026-03-18 | LivingMed Biotech S.R.L. | Genetically modified clostridium strains and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE69002817T2 (de) * | 1989-11-28 | 1993-12-09 | Wellcome Found | Vakzine. |
| US6280721B1 (en) * | 1989-12-18 | 2001-08-28 | Valent Biosciences, Inc. | Production of Bacillus thuringiensis integrants |
| JP3415145B2 (ja) * | 1991-03-05 | 2003-06-09 | ザ ウエルカム ファウンデーション リミテッド | 弱毒化細菌における組換えタンパク質の発現 |
| US5340577A (en) * | 1992-07-29 | 1994-08-23 | The United States Of America, As Represented By The Secretary Of Agriculture | Probiotic for control of salmonella |
| GB9401787D0 (en) * | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccine compositions |
| GB9400650D0 (en) * | 1994-01-14 | 1994-03-09 | Smithkline Beecham Biolog | Expression of surface lazer proteins |
| US5533973A (en) * | 1995-01-13 | 1996-07-09 | Abbott Laboratories | Alteration of nutritional product during enteral tube feeding |
| US5531681A (en) * | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
| US5531734A (en) * | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Method of altering composition of nutritional product during enteral tube feeding |
| US5800821A (en) * | 1995-03-10 | 1998-09-01 | New England Medical Center Hospitals, Inc. | Bacterial spores as a heat stable vaccine delivery system |
| US5707353A (en) * | 1995-12-21 | 1998-01-13 | Abbott Laboratories | Oral administration of beneficial agents |
| WO1997035612A1 (fr) * | 1996-03-23 | 1997-10-02 | The Research Foundation For Microbial Diseases Of Osaka University | Antigene a fragment fonctionnel de la toxine du tetanos, et vaccin contre le tetanos |
| US5707127A (en) * | 1996-06-26 | 1998-01-13 | Kain; Meira | Three-dimensional image viewing apparatus |
| DK0862863T4 (da) * | 1997-01-09 | 2008-12-01 | Nestle Sa | Kornprodukt indeholdende probiotika |
| US7923216B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
| US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
| US6730499B1 (en) * | 1998-07-03 | 2004-05-04 | Research Corporation Technologies, Inc. | Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1 |
| US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
| US6090417A (en) * | 1999-03-24 | 2000-07-18 | Kraft Foods, Inc. | Nutritional fortification of natural cheese and method of making |
| US7186560B2 (en) * | 1999-09-21 | 2007-03-06 | Rutgers, The State University Of New Jersey | High level expression of immunogenic proteins in the plastids of higher plants |
| GB0009470D0 (en) * | 2000-04-17 | 2000-06-07 | Univ Southampton | Materials and methods relating to immune responses to fusion proteins |
| EP1292686A1 (en) * | 2000-06-07 | 2003-03-19 | Smittskyddsinstitutet | Gene expression cassette and its use |
| US6881558B1 (en) * | 2000-06-26 | 2005-04-19 | The Trustees Of The University Of Pennsylvania | Expression system for cloning toxic genes |
| US20030165538A1 (en) * | 2000-06-26 | 2003-09-04 | Maxygen Incorporated | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| US20020150594A1 (en) * | 2000-06-26 | 2002-10-17 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| KR20020045400A (ko) * | 2000-12-08 | 2002-06-19 | 반재구 | 포자 표면발현 방법 |
| GB0130789D0 (en) * | 2001-12-21 | 2002-02-06 | King S College London | Application of spores |
-
2002
- 2002-03-07 GB GBGB0205376.7A patent/GB0205376D0/en not_active Ceased
-
2003
- 2003-03-07 AU AU2003214391A patent/AU2003214391A1/en not_active Abandoned
- 2003-03-07 WO PCT/GB2003/000966 patent/WO2003074681A1/en not_active Ceased
- 2003-03-07 EP EP03709962A patent/EP1495110A1/en not_active Withdrawn
- 2003-03-07 RU RU2004129739/13A patent/RU2004129739A/ru not_active Application Discontinuation
- 2003-03-07 JP JP2003573134A patent/JP2005519123A/ja not_active Withdrawn
- 2003-03-07 CN CNA038054248A patent/CN1639322A/zh active Pending
- 2003-03-07 US US10/506,749 patent/US20050287168A1/en not_active Abandoned
- 2003-03-07 KR KR10-2004-7013611A patent/KR20040099293A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1639322A (zh) | 2005-07-13 |
| AU2003214391A1 (en) | 2003-09-16 |
| RU2004129739A (ru) | 2005-09-20 |
| WO2003074681A1 (en) | 2003-09-12 |
| JP2005519123A (ja) | 2005-06-30 |
| EP1495110A1 (en) | 2005-01-12 |
| GB0205376D0 (en) | 2002-04-24 |
| US20050287168A1 (en) | 2005-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duc et al. | Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery | |
| Clark-Curtiss et al. | Salmonella vaccines: conduits for protective antigens | |
| US8703153B2 (en) | Salmonella vectored vaccines against Chlamydia and methods of use | |
| TWI338045B (en) | Recombinant attenuated clostridium organisms and vaccine | |
| KR102157964B1 (ko) | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 돼지의 아프리카 돼지열병 백신 | |
| CA2687468A1 (en) | Live bacterial vaccine | |
| KR102212503B1 (ko) | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 넙치의 스쿠티카증 백신 | |
| KR102071743B1 (ko) | 신규의 약독화된 시겔라 생백신 | |
| KR102107332B1 (ko) | CRISPR/Cas9 기반 Bacillus subtillis 유전체 편집 메커니즘을 이용한 콜레라 백신 | |
| TWI221847B (en) | Clostridium perfringens vaccine | |
| Alimolaei et al. | A recombinant probiotic, Lactobacillus casei, expressing the Clostridium perfringens α-toxoid, as an orally vaccine candidate against gas gangrene and necrotic enteritis | |
| KR102212505B1 (ko) | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 벌의 낭충봉아부패 백신 | |
| JP2002507414A (ja) | ワクチンに使用する弱毒化細菌 | |
| US20050232947A1 (en) | Bacterial spores | |
| US7399474B2 (en) | Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same | |
| JP2002509421A (ja) | グラム陽性菌の表面上のハイブリッド表面タンパク質の供給及び発現 | |
| KR20040099293A (ko) | 재조합 포자 | |
| AU2001255543A1 (en) | Isolation and characterization of the CSA operon (ETEC-CS4 pili) and methods of using same | |
| US7759106B2 (en) | Construction of live attenuated Shigella vaccine strains that express CFA/I antigens (CfaB and CfaE) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic E. coli | |
| AU751517B2 (en) | TGC method for inducting targeted somatic transgenesis | |
| US7090850B2 (en) | Proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections | |
| CN101611143B (zh) | 将肽递送入胃粘膜的方法和装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20040901 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |